Pfizer Inc
NYSE: PFE
▼
43.84
-0.53
-1.19%
1 Day
-
Open
43.89
-
Previous Close
44.37
-
Volume (Avg)
10.83M (9.92M)
-
Day's Range
43.70-44.24
-
52Wk Range
33.20-45.81
-
Market Cap.
256.47B
-
Dividend Rate (Yield)
1.36 (3.07%)
-
Beta
-
-
Shares Outstanding
-
-
P/E Ratio (EPS)
11.86 (-)
Top Stories
-
Pfizer (PFE) Q3 Earnings Preview: What to Expect
Zacks Investment Research 1 hr agoWall Street expects a year-over-year increase in earnings on higher revenues when Pfizer (PFE - Free Report) reports results for the quarter ended September 2018. While this widely-known consensus outlook is important in gauging the company's earnings ...
-
Pfizer and Bain Capital launch new biotech aimed at CNS therapies
Seeking Alpha -
Bain Capital And Pfizer Create New CNS Company Cerevel Therapeutics
Nasdaq -
Bain Capital and Pfizer (PFE) Create Cerevel Therapeutics
StreetInsider -
In 2014 They Battled For Control. Now Pfizer's Read And AstraZeneca's Soriot In Different Places
Forbes 5 hrs ago -
Bain Capital teams with Pfizer to create new neuroscience-focused company
CNBC -
Pfizer (PFE) Stock Moves -0.29%: What You Should Know
Zacks Investment Research -
Recon: Pfizer, Bain Launch CNS-Focused Startup
RAPS -
Pfizer, Bain Form Startup Focusing on Central Nervous Disorders
Bloomberg L.P. -
Pfizer, Bain Capital Create New CNS Company
Private Equity News -
Pfizer, Bain Capital launch startup to fight nervous system diseases
Becker's Hospital Review -
Bone Cancer Diagnosis and Therapeutics Market 2018 Global Analysis By Key Players – Amgen, Novartis, Bayer, Pfizer, Celldex Therapeutics
openpr.com -
Global Axial Spondyloarthritis Treatment Market 2018-2022 - Key Vendors are AbbVie, Amgen, Johnson & Johnson, Pfizer & UCB - ResearchAndMarkets.com
Business Wire -
Bain Capital and Pfizer form Cerevel Therapeutics, Bain commits $350 mln
PE Hub -
Bain, Pfizer launch biotech startup to tackle brain disorders
The Business Journals 3 hrs ago -
US FDA approves Pfizer’s PARP inhibitor for metastatic breast cancer
In-PharmaTechnologist -
Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS Company
The Business Journals -
Bain’s Adam Koppel commits $350M to launching a new biotech that is carving out Pfizer’s neuro pipeline
ENDPOINTS NEWS
